GENFLOW BIOSCIENCES PLC

Board/Management Information • Nov 8, 2023

National Storage Mechanism | Additional information

RNS Number : 7060S

Genflow Biosciences PLC

08 November 2023

8 November 2023

Genflow Biosciences Plc

("Genflow" or "the Company")

Appointment of Joint Broker

The Company (LSE:GNF) (OTCQB:GENFF), is pleased to announces today that it has appointed Capital Plus Partners Ltd to act as Joint Broker, alongside Clear Capital Markets, with immediate effect.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

Genflow Biosciences Plc
Dr Eric Leire Chief Executive Officer	+32 477 495 881
Clear Capital Markets
Joint Corporate Broker  Bob Roberts	+44 203 869 6080
Capital Plus Partners Ltd
Joint Corporate Broker  Dominic Berger	+44 203 821 6167

About Genflow Biosciences

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase our understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPKZMGMRNRGFZM